Business Context and Reporting Period
This Form 8-K filing by Surrozen, Inc. (SRZN) reports a material event occurring on October 14, 2025. The Company, an emerging growth company incorporated in Delaware, operates in the biotechnology sector providing antibody discovery services.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity figures. It references a terminated Collaboration Agreement with TCGFB, Inc. that included potential consideration of up to $6.0 million in aggregate payments plus third-party costs, contingent on vesting conditions. The Company also held a warrant for up to 3.4 million shares of TCGFB common stock under the agreement.
Material Changes
- Termination of Agreement: TCGFB, Inc. elected to terminate the Collaboration Agreement dated October 31, 2024, for convenience.
- Effective Date: The termination is effective as of November 13, 2025.
- Financial Impact: No termination penalties will be incurred by either party. The potential revenue stream of up to $6.0 million and the associated warrant are no longer guaranteed under the original terms.
- Related Party Status: The terminated agreement was a related party transaction involving The Column Group, which holds more than 5% of Surrozen's common stock, and Dr. Kutzkey, a member of Surrozen's board of directors.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future strategy, or specific risk factors beyond the immediate loss of the collaboration. The termination was executed without penalty, suggesting no immediate litigation risk regarding the agreement's dissolution. The loss of the potential $6.0 million revenue and the TCGFB warrant represents a reduction in expected future assets and income.
Investor Verification Checklist
- Verify the status of any payments already received from TCGFB prior to the termination notice.
- Confirm the vesting status of the 3.4 million TCGFB warrants and whether any portion remains exercisable post-termination.
- Review the Company's pipeline for other antibody discovery contracts to assess the impact of this termination on future revenue projections.
- Check for any subsequent filings regarding the relationship with The Column Group or Dr. Kutzkey.